Walleye Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Walleye Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,600	Closed	-$416K	–	5811
2023 Q3	$416K	Buy	3,600 +2,900	+414%	+$312K	﹤0.01%	2955
2023 Q2	$72K	Buy	+700	New	+$73.9K	﹤0.01%	3531
2023 Q1	–	Sell	-1,500	Closed	-$171K	–	4708
2022 Q4	$171K	Buy	+1,500	New	+$125K	﹤0.01%	2138
2020 Q1	–	Sell	-9,900	Closed	-$358K	–	2054
2019 Q4	$358K	Buy	9,900 +4,100	+71%	+$126K	0.02%	839
2019 Q3	$158K	Buy	5,800 +1,800	+45%	+$46.5K	0.01%	1285
2019 Q2	$96K	Sell	4,000 -7,300	-65%	-$185K	0.01%	1239
2019 Q1	$299K	Buy	+11,300	New	+$268K	0.05%	604

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Walleye Capital's HZNP Position: Q3 2023 in Review

Walleye Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 45,055 shares — an estimated $4.84M sold.

Walleye Capital first reported a position in HZNP in Q1 2019 and held it in 10 quarters. The position peaked at $6.41M in Q1 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Walleye Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Walleye Capital sold 45,055 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $4.84M.
Walleye Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 10 quarters.
Walleye Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.41M in Q1 2023.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Walleye Capital's 13F filing for Q3 2023, filed 14 Nov 2023.